pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-103b-1 |
Genomic Coordinates | chr5: 168560904 - 168560965 |
Description | Homo sapiens miR-103b-1 stem-loop |
Comment | None |
RNA Secondary Structure | ![]() |
Associated Diseases | ![]() |
pre-miRNA | hsa-mir-103b-2 |
Genomic Coordinates | chr20: 3917502 - 3917563 |
Description | Homo sapiens miR-103b-2 stem-loop |
Comment | None |
RNA Secondary Structure | ![]() |
Associated Diseases | ![]() |
Mature miRNA Information | ||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-103b | |||||||||||||||||||||
Sequence | 1| UCAUAGCCCUGUACAAUGCUGCU |23 | |||||||||||||||||||||
Evidence | Experimental | |||||||||||||||||||||
Experiments | ChIP-seq | DRVs in miRNA |
|
|||||||||||||||||||
SNPs in miRNA |
|
|||||||||||||||||||||
Putative Targets |
Gene Information | |
---|---|
Gene Symbol | AKR7L |
Experimental Support 1 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | HEK293S |
Location of target site | 3'UTR |
Tools used in this research | TargetScan , miRTarCLIP , Piranha |
Original Description (Extracted from the article) |
...
HITS-CLIP data was present in GSM1084045. RNA binding protein: AGO2. Condition:CLIP_arsenite_rep3
HITS-CLIP data was present in GSM1084065. RNA binding protein: AGO2. Condition:CLIP_emetine_AbnovaAb
HITS-CLIP data was present in GSM1084078. RNA binding protein: AGO2. Condition:CLIP_nohippuristanol_rep2_AbnovaAb
... - Karginov FV; Hannon GJ, 2013, Genes & development. |
Article |
- Karginov FV; Hannon GJ - Genes & development, 2013
When adapting to environmental stress, cells attenuate and reprogram their translational output. In part, these altered translation profiles are established through changes in the interactions between RNA-binding proteins and mRNAs. The Argonaute 2 (Ago2)/microRNA (miRNA) machinery has been shown to participate in stress-induced translational up-regulation of a particular mRNA, CAT-1; however, a detailed, transcriptome-wide understanding of the involvement of Ago2 in the process has been lacking. Here, we profiled the overall changes in Ago2-mRNA interactions upon arsenite stress by cross-linking immunoprecipitation (CLIP) followed by high-throughput sequencing (CLIP-seq). Ago2 displayed a significant remodeling of its transcript occupancy, with the majority of 3' untranslated region (UTR) and coding sequence (CDS) sites exhibiting stronger interaction. Interestingly, target sites that were destined for release from Ago2 upon stress were depleted in miRNA complementarity signatures, suggesting an alternative mode of interaction. To compare the changes in Ago2-binding patterns across transcripts with changes in their translational states, we measured mRNA profiles on ribosome/polysome gradients by RNA sequencing (RNA-seq). Increased Ago2 occupancy correlated with stronger repression of translation for those mRNAs, as evidenced by a shift toward lighter gradient fractions upon stress, while release of Ago2 was associated with the limited number of transcripts that remained translated. Taken together, these data point to a role for Ago2 and the mammalian miRNAs in mediating the translational component of the stress response.
LinkOut: [PMID: 23824327]
|
Experimental Support 2 for Functional miRNA-Target Interaction | |||||||
---|---|---|---|---|---|---|---|
miRNA:Target | ---- | ||||||
Validation Method |
|
||||||
Conditions | Prostate Tissue | ||||||
Location of target site | 3'UTR | ||||||
Tools used in this research | TargetScan , miRTarCLIP , Piranha | ||||||
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in SRX1760631. RNA binding protein: AGO2. Condition:AGO-CLIP-22RV1_B
... - Hamilton MP; Rajapakshe KI; Bader DA; Cerne et al., 2016, Neoplasia (New York, N.Y.). |
||||||
miRNA-target interactions (Provided by authors) |
|
||||||
Article |
- Hamilton MP; Rajapakshe KI; Bader DA; Cerne et al. - Neoplasia (New York, N.Y.), 2016
MicroRNA (miRNA) deregulation in prostate cancer (PCa) contributes to PCa initiation and metastatic progression. To comprehensively define the cancer-associated changes in miRNA targeting and function in commonly studied models of PCa, we performed photoactivatable ribonucleoside-enhanced cross-linking immunoprecipitation of the Argonaute protein in a panel of PCa cell lines modeling different stages of PCa progression. Using this comprehensive catalogue of miRNA targets, we analyzed miRNA targeting on known drivers of PCa and examined tissue-specific and stage-specific pathway targeting by miRNAs. We found that androgen receptor is the most frequently targeted PCa oncogene and that miR-148a targets the largest number of known PCa drivers. Globally, tissue-specific and stage-specific changes in miRNA targeting are driven by homeostatic response to active oncogenic pathways. Our findings indicate that, even in advanced PCa, the miRNA pool adapts to regulate continuing alterations in the cancer genome to balance oncogenic molecular changes. These findings are important because they are the first to globally characterize miRNA changes in PCa and demonstrate how the miRNA target spectrum responds to staged tumorigenesis.
LinkOut: [PMID: 27292025]
|
CLIP-seq Support 1 for dataset GSM1084045 | |
---|---|
Method / RBP | HITS-CLIP / AGO2 |
Cell line / Condition | HEK293S / CLIP_arsenite_rep3 |
Location of target site | ENST00000420396.2 | 3UTR | UGACUGUGCCACUGCACUCCAGCCUGGGCGAC |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 23824327 / GSE44404 |
CLIP-seq Viewer | Link |
CLIP-seq Support 2 for dataset GSM1084065 | |
---|---|
Method / RBP | HITS-CLIP / AGO2 |
Cell line / Condition | HEK293S / CLIP_emetine_AbnovaAb |
Location of target site | ENST00000420396.2 | 3UTR | AUGACUGUGCCACUGCACUCCAGCCUGGGC |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 23824327 / GSE44404 |
CLIP-seq Viewer | Link |
CLIP-seq Support 3 for dataset GSM1084078 | |
---|---|
Method / RBP | HITS-CLIP / AGO2 |
Cell line / Condition | HEK293S / CLIP_nohippuristanol_rep2_AbnovaAb |
Location of target site | ENST00000420396.2 | 3UTR | UGACUGUGCCACUGCACUCCAGCCUGG |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 23824327 / GSE44404 |
CLIP-seq Viewer | Link |
MiRNA-Target Expression Profile | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | |||||||
---|---|---|---|---|---|---|---|
|
53 hsa-miR-103b Target Genes:
Functional analysis:
ID![]() |
Target | Description | Validation methods |
![]() |
![]() |
|||||||
Strong evidence | Less strong evidence | |||||||||||
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
|||||
MIRT218386 | E2F3 | E2F transcription factor 3 | ![]() |
![]() |
2 | 2 | ||||||
MIRT404221 | RPL7L1 | ribosomal protein L7 like 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT441502 | SPG20 | spartin | ![]() |
![]() |
2 | 6 | ||||||
MIRT444124 | ZNRF3 | zinc and ring finger 3 | ![]() |
![]() |
2 | 2 | ||||||
MIRT454236 | OSBPL10 | oxysterol binding protein like 10 | ![]() |
![]() |
2 | 4 | ||||||
MIRT457919 | ZNF212 | zinc finger protein 212 | ![]() |
![]() |
2 | 2 | ||||||
MIRT462254 | LAMA4 | laminin subunit alpha 4 | ![]() |
![]() |
2 | 2 | ||||||
MIRT463176 | ZNF281 | zinc finger protein 281 | ![]() |
![]() |
2 | 2 | ||||||
MIRT472355 | TSPAN1 | tetraspanin 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT474133 | LIN54 | lin-54 DREAM MuvB core complex component | ![]() |
![]() |
2 | 4 | ||||||
MIRT494946 | IFFO2 | intermediate filament family orphan 2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT497403 | NPY4R | neuropeptide Y receptor Y4 | ![]() |
![]() |
2 | 2 | ||||||
MIRT497641 | GLDN | gliomedin | ![]() |
![]() |
2 | 2 | ||||||
MIRT505340 | TMEM245 | transmembrane protein 245 | ![]() |
![]() |
2 | 6 | ||||||
MIRT505680 | SESTD1 | SEC14 and spectrin domain containing 1 | ![]() |
![]() |
2 | 6 | ||||||
MIRT510706 | SREK1IP1 | SREK1 interacting protein 1 | ![]() |
![]() |
2 | 6 | ||||||
MIRT512198 | C1orf43 | chromosome 1 open reading frame 43 | ![]() |
![]() |
2 | 2 | ||||||
MIRT522089 | NUFIP2 | NUFIP2, FMR1 interacting protein 2 | ![]() |
![]() |
2 | 4 | ||||||
MIRT525074 | FRK | fyn related Src family tyrosine kinase | ![]() |
![]() |
2 | 2 | ||||||
MIRT531276 | PPIL3 | peptidylprolyl isomerase like 3 | ![]() |
![]() |
2 | 2 | ||||||
MIRT535119 | PLXNA2 | plexin A2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT540836 | GNAT1 | G protein subunit alpha transducin 1 | ![]() |
![]() |
2 | 4 | ||||||
MIRT541018 | WIPI2 | WD repeat domain, phosphoinositide interacting 2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT545752 | CA12 | carbonic anhydrase 12 | ![]() |
![]() |
2 | 4 | ||||||
MIRT546404 | SRP9 | signal recognition particle 9 | ![]() |
![]() |
2 | 2 | ||||||
MIRT547991 | HCFC2 | host cell factor C2 | ![]() |
![]() |
2 | 4 | ||||||
MIRT554502 | SAE1 | SUMO1 activating enzyme subunit 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT558360 | DMTF1 | cyclin D binding myb like transcription factor 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT558863 | CD2AP | CD2 associated protein | ![]() |
![]() |
2 | 2 | ||||||
MIRT559939 | ZNF567 | zinc finger protein 567 | ![]() |
![]() |
2 | 2 | ||||||
MIRT566300 | PPM1A | protein phosphatase, Mg2+/Mn2+ dependent 1A | ![]() |
![]() |
2 | 2 | ||||||
MIRT567490 | FOXK1 | forkhead box K1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT617139 | ZNF556 | zinc finger protein 556 | ![]() |
![]() |
2 | 2 | ||||||
MIRT625400 | AKR7L | aldo-keto reductase family 7 like (gene/pseudogene) | ![]() |
![]() |
2 | 2 | ||||||
MIRT626491 | CEP89 | centrosomal protein 89 | ![]() |
![]() |
2 | 2 | ||||||
MIRT629487 | GSN | gelsolin | ![]() |
![]() |
2 | 4 | ||||||
MIRT638456 | PLXDC2 | plexin domain containing 2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT648498 | CMBL | carboxymethylenebutenolidase homolog | ![]() |
![]() |
2 | 2 | ||||||
MIRT654845 | PPM1L | protein phosphatase, Mg2+/Mn2+ dependent 1L | ![]() |
![]() |
2 | 2 | ||||||
MIRT664587 | HSD17B12 | hydroxysteroid 17-beta dehydrogenase 12 | ![]() |
![]() |
2 | 2 | ||||||
MIRT664977 | TDRD1 | tudor domain containing 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT665028 | ELK1 | ELK1, ETS transcription factor | ![]() |
![]() |
2 | 2 | ||||||
MIRT666043 | STON2 | stonin 2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT668863 | CRY2 | cryptochrome circadian clock 2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT669297 | C17orf85 | nuclear cap binding subunit 3 | ![]() |
![]() |
2 | 2 | ||||||
MIRT680975 | DCAF17 | DDB1 and CUL4 associated factor 17 | ![]() |
![]() |
2 | 2 | ||||||
MIRT682267 | RS1 | retinoschisin 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT685283 | KIAA1143 | KIAA1143 | ![]() |
![]() |
2 | 2 | ||||||
MIRT693375 | PIGP | phosphatidylinositol glycan anchor biosynthesis class P | ![]() |
![]() |
2 | 2 | ||||||
MIRT701785 | MSL1 | male specific lethal 1 homolog | ![]() |
![]() |
2 | 2 | ||||||
MIRT709373 | SPECC1 | sperm antigen with calponin homology and coiled-coil domains 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT715154 | IL12B | interleukin 12B | ![]() |
![]() |
2 | 2 | ||||||
MIRT734499 | ADAMTS5 | ADAM metallopeptidase with thrombospondin type 1 motif 5 | ![]() |
![]() |
![]() |
3 | 0 |
miRNA-Drug Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|